Since the Rappaport classification provides little information for the prognosis of extranodal non-Hodgkin’s lymphoma (NHL), the Kiel classification was used for 71 patients with head and neck extranodal NHL, stages IE and HE. The ratios of low grade malignancy (LGM) and high grade malignancy (HGM) were about 60 and 40%, respectively. The lesions comprised 37 non-thyroid lymphomas and 34 thyroid lymphomas. 8 cases of thyroid NHL did not fit into a rigid classification scheme, and were separatively analyzed. In the whole group of patients and the subset of 37 patients with non-thyroid NHL, the 5-year survival rates for LGM were significantly better than for HGM. LGM showed a more favorable prognosis than HGM in 26 patients with thyroid NHL, but the difference was not statistically significant. 8 cases of thyroid NHL showed diffuse proliferation of centrocytes or centroblasts in which various numbers of nodules consisting of large centroblasts and centrocytes with high mitotic activity were scattered. The cases behaved as HGM. From these findings, we suggest that the Kiel classification in extranodal NHL is helpful.

Keywords:
Extranodal lymphoma, Non-Hodgkin’s lymphoma, Histology, Survival, Head and neck
This content is only available via PDF.
© 1984 S. Karger AG, Basel
1984
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.